Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI

Dora Il'yasova, Frances Wang, Ivan Spasojevic, Karel Base, Ralph B D'Agostino Jr, Lynne E Wagenknecht, Dora Il'yasova, Frances Wang, Ivan Spasojevic, Karel Base, Ralph B D'Agostino Jr, Lynne E Wagenknecht

Abstract

Levels of four urinary F(2)-isoprostanes (F(2)-IsoPs) were examined in a large sample of the Insulin Resistance Atherosclerosis Study (IRAS) multiethnic cohort: 237 African Americans (AAs), 342 non-Hispanic whites (NHWs), and 275 Hispanic whites (HWs). F(2)-IsoP isomers - iPF2a-III, 2,3-dinor-iPF2a-III, iPF2a-VI, and 8,12-iso-iPF2a-VI - were measured in 854 urine samples using liquid chromatography with tandem mass spectrometry detection. In AAs, levels of all four F(2)-IsoPs were lower compared with NHWs and HWs (P values <0.05). When stratified by BMI, this gap was not observed among participants with normal BMI but appeared among overweight participants and increased among obese participants. Examining the slopes of the associations between BMI and F(2)-IsoPs showed no association between these variables among AAs (P values >0.2), and positive associations among whites (P values <0.05). Taking into account that positive cross-sectional associations between systemic F(2)-IsoP levels and BMI have been consistently demonstrated in many study populations, the lack of such an association among AAs reveals a new facet of racial/ethnic differences in obesity-related risk profiles.

Figures

Figure 1
Figure 1
Association between 2,3-dinor-iPF2α-III and BMI by race/ethnicity adjusted for age and gender. (A) Age- and gender-adjusted mean (standard errors) of urinary 2,3-dinor-iPF(2a)-III levels by BMI categories among AAs (50/115/71), NHWs (110/143/88), and HWs (64/127/84); mean values are compared with AAs within each BMI category. (B) Slopes for the regression of age- and gender-adjusted BMI against 2,3-dinor-iPF(2a)-III; p-value is presented for the interaction term between race and BMI.

References

    1. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal. 2008;10:1405–34.
    1. Keaney JF, Jr., Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434–9.
    1. Meigs JB, Larson MG, Fox CS, Keaney JF, Jr., Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care. 2007;30:2529–35.
    1. Il’yasova D, Spasojevic I, Base K, et al. Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. Diabetes Care. 2012;35:173–4.
    1. Il’yasova D, Wang F, Spasojevic I, Base K, D’Agostino RJ, Wagenknecht L. Urinary F2-Isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity. 2011
    1. Kanaya AM, Wassel CL, Stoddard PJ, et al. F2-isoprostanes and adiposity in older adults. Obesity (Silver Spring) 2011;19:861–7.
    1. Il’yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res. 2005;13:1638–44.
    1. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.
    1. Kaiyala KJ, Schwartz MW. Toward a more complete (and less controversial) understanding of energy expenditure and its role in obesity pathogenesis. Diabetes. 2011;60:17–23.
    1. Weyer C, Pratley RE, Salbe AD, Bogardus C, Ravussin E, Tataranni PA. Energy Expenditure, Fat Oxidation, and Body Weight Regulation: A Study of Metabolic Adaptation to Long-Term Weight Change. J Clin Endocrinol Metab. 2000;85:1087–94.
    1. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, GA: 2011. Ref Type: Report.
    1. Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 2003;40(Suppl 1):S302–S304.
    1. Goran MI. Ethnic-specific pathways to obesity-related disease: the Hispanic vs. African-American paradox. Obesity (Silver Spring) 2008;16:2561–5.
    1. Lutsey PL, Pereira MA, Bertoni AG, Kandula NR, Jacobs DR., Jr Interactions between race/ethnicity and anthropometry in risk of incident diabetes: the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2010;172:197–204.
    1. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res. 2007;48:1607–17.
    1. WHO Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1985;727:1–113.
    1. Pratico D, Barry OP, Lawson JA, et al. IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A. 1998;95:3449–54.
    1. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28:505–13.
    1. Zhang H, Il’yasova D, Sztaray J, Young SP, Wang F, Millington DS. Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Anal Biochem. 2010;399:302–4.
    1. Il’yasova D, Spasojevic I, Wang F, et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev. 2010;19:1506–10.
    1. Dorjgochoo T, Gao YT, Chow WH, et al. Obesity, age, and oxidative stress in middle-aged and older women. Antioxid Redox Signal. 2011;14:2453–60.
    1. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab. 2003;88:4673–6.
    1. Weyer C, Snitker S, Bogardus C, Ravussin E. Energy metabolism in African Americans: potential risk factors for obesity. Am J Clin Nutr. 1999;70:13–20.
    1. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005;113:192–200.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren